Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Levonorgestrel/Ethinyl Estradiol · 5 trials · 4 indications
| Name | Type | Description |
|---|---|---|
| Levonorgestrel/Ethinyl Estradiol | DRUG | - |
| Levonorgestrel 90 mg/Ethinyl Estradiol 20 mg | DRUG | - |
Inclusion Criteria: * Generally healthy, women aged 18 to 49 years. * History of severe PMS symptoms over the last year, as determined by the investigator. * Regular 21 to 35 day menstrual cycle for 2 months prior to first study visit. Exclusion Criteria: * Major depressive disorder requiring ant...
Levonorgestrel is a small molecule drug being developed by Pfizer, Inc. for use as an oral contraceptive and for contraception. It is also studied for menstruation disturbances, premenstrual syndrome, ovulation, and in healthy volunteers. It is currently in clinical development and is not approved.
Levonorgestrel is developed by Pfizer, Inc., which trades under the ticker symbol PFE. The drug is being studied in clinical trials for contraception and premenstrual syndrome, among other indications.
Levonorgestrel is in Phase 2 of clinical development. It has completed two Phase 3 trials and one Phase 1 trial, with a total of two completed trials and no active trials. It is investigational and not yet approved.
Levonorgestrel has been studied in clinical trials including NCT00128934, NCT00161681, NCT00195559, and NCT00319163. These trials evaluated the drug for premenstrual dysphoric disorder, premenstrual syndrome, and healthy volunteers, with enrollment ranging from 26 to 744 participants.
Levonorgestrel is often studied in combination with ethinyl estradiol, referred to as LNG/EE. Clinical trials such as NCT00128934 and NCT00161681 evaluate this combination for conditions like premenstrual dysphoric disorder and premenstrual syndrome.